Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 3 Study of OTO-104 Given as a Single Intratympanic Injection in Subjects With Unilateral Meniere's Disease

NCT02612337 is registered in ClinicalTrials.gov with Otonomy, Inc. as lead sponsor.

NCT NCT02612337
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02612337 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 3 Study of OTO-104 Given as a Single Intratympanic Injection in Subjects With Unilateral Meniere's Disease
Lead sponsor
Otonomy, Inc.
Phase
Phase 3
Overall status
Completed
Start date
October 27, 2015
Completion date
July 18, 2017
Enrollment
166 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

meniere's disease